secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000719135-23-000025
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q1 revenue $12.1M (-3% YoY); raises FY2023 guidance; FDA updates Safety Communication
--------------------------------------------------------------------------------

- Total revenue $12.1M (-3% YoY); Advanced Energy $9.7M (-10%); OEM $2.5M (+46%).
- Net loss $3.5M ($0.10/share) improved from $5.9M loss in Q1 2022; Adjusted EBITDA loss $4.0M.
- Raises FY2023 total revenue guidance to $59-62M (prior $58-61M); Advanced Energy $51-54M; net loss expected ~$10.5M.
- FDA updated Safety Communication on May 10 clearing Renuvion APR handpiece for subcutaneous soft tissue coagulation post-liposuction.
- Closed sale-leaseback of Clearwater facility for $6.6M net cash; secured $35M credit facility with MidCap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/0000719135-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913523000025/apyx-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000719135-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer